HitGen of Chengdu announced a drug discovery collaboration with Sanofi that will identify novel small molecule leads for targets of interest. To discover lead molecules, HitGen will use its DNA-encoded library, which contains over 150 billion novel compounds. The candidates will be licensed exclusively to Sanofi. HitGen is a partnering powerhouse with over 50 companies already signed up to use its drug discovery services. In the Sanofi deal, HitGen will receive upfront payments and be eligible for milestones, though financial details were not disclosed.
Source: China Biotoday
